Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NiTraSarc Phase II Trial
2017-001083-38Phase 2Completed
- Sponsor
- Universitätsklinikum Greifswald
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, trabectedin in soft tissue sarcoma (STS), leiomyosarcoma (LMS), sponsored by Universitätsklinikum Greifswald. Started Nov 2017; status: completed.
02
Drugs
nivolumabtrabectedin
03
Conditions
soft tissue sarcoma (STS)leiomyosarcoma (LMS)
Beyond the preview
Go deeper on 2017-001083-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001083-38.